Cambrex announced that Snapdragon Chemistry, a Cambrex company, has developed a new liquid-phase peptide synthesis (LPPS) technology utilizing active pharmaceutical ingredient (API) batch reactors and continuous flow.
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides.
Active pharmaceutical ingredients manufacturer EuroAPI has agreed to acquire BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. Biano is to become a EuroAPI company but retain its corporate brand.
Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has signed another order worth more than 500 million Swiss francs – or $531 million – to supply large volumes of peptides following a joint development project. The identity of the customer has not been disclosed.
Agilent Technologies has selected Turner Construction to build its previously announced new API plant in Frederick, Colorado, USA. The project is scheduled for completion in 2026.
British pharma GSK has entered into a four-year collaboration with US clinical-stage genetic medicines company Wave Life Sciences to advance oligonucleotide therapeutics, including Wave’s preclinical RNA-editing program targeting alpha-1 antitrypsin deficiency (AATD), an inherited disorder that can cause lung and liver disease.
Interest in oligonucleotide therapeutics has grown, as has the market demand, since their emergence as a new drug modality two decades ago.
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
Swiss peptide and oligonucleotide specialist Bachem has agreed to buy an undeveloped site in Sisslerfeld from DSM. It has completed the purchase of a first plot, with others to follow in the coming years.
Bachem, a Swiss specialist developer and manufacturer of peptides and oligonucleotides, has announced the signing of two major contracts for supplying large volumes of peptides over the next two years. The orders are worth 25 million and 150 million Swiss francs for 2023 and 2024, respectively.
The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment a few years ago and meanwhile has passed certain milestones on its way to become a preferred oligonucleotide manufacturing partner for pharmaceutical companies.
The global market for oligonucleotide therapeutics is expanding rapidly. Bachem, an innovation-driven company based in Bubendorf, Switzerland, has entered this competitive environment in 2019.
